Nat Genet: scientists develop new methods of cancer precision medicine, which can give drugs one-on-one with precision

June 24, 2018 / biool / - recently, scientists from the Department of systems biology of Columbia University have developed a new precise oncology network, which is used to systematically determine the priority of tumor dependent drugs targeting a single patient, and to find some drugs for the most appropriate treatment of a patient Relevant research was recently published in nature In genetics, it is entitled "a precision oncology approach to the forensic targeting of mechanical dependencies in neuroendocrine tumors" Photo source: cuimc / California lab identified the synergistic effects of the main regulatory proteins regulating the state of tumor cells through systematic drug disruption experiments, and then prioritized the drugs according to their ability to reverse these effects The method was tested in 212 patients with gastrointestinal neuroendocrine tumors (GEP NENS), a rare malignant tumor originating from the pancreas and gastrointestinal tract This analysis found several major regulatory proteins, including the key regulatory proteins of neuroendocrine lineage and immune escape, and the role of them as key tumor dependent mediators was verified by experiments Using 107 compounds to treat gep-net-derived cells, the researchers found that entenole, an HDAC class 1 inhibitor, is a powerful inhibitor of major regulatory proteins in 42% of patients with metastatic GEP-NET, which can clear tumors in vivo This method may be able to make up for the shortcomings of the existing precise oncology methods Reference: Andrea California et al A precision oncology approach to the forensic targeting of mechanical dependencies in neuroendocrine tumors, Nature Genetics, DOI: 10.1038/s41588-018-0138-4, https://